Extrapyramidal side effects during chronic combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys

European Archives of Psychiatry and Clinical Neuroscience

Volumn 249, Issue 5, 1999, Pages 221-226

  Peacock, Linda ^a   Jensen, G ^a   Nicholson, K ^a   Gerlach, J ^a  

^a Sct Hans Hospital   (Denmark)

Author keywords

Dopamine D1 antagonist; Dopamine D2 antagonist; Dyskinesia; Dystonia; Extrapyramidal side effects; Monkey; Parkinsonism

Indexed keywords

8 CHLORO 5 (7 BENZOFURANYL) 7 HYDROXY 3 METHYL 2,3,4,5 TETRA HYDRO 1H 3 BENZAZEPINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; RACLOPRIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BRADYKINESIA; DRUG TOLERANCE; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; MALE; MONKEY; NONHUMAN; PRIORITY JOURNAL;

EID: 0032744827     PISSN: 09401334     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004060050090     Document Type: Article

References (20)

1. Kistrup K, Gerlach J (1987) Selective D1 and D2 receptor manipulation in Cebus monkeys: relevance for dystonia and dyskinesia in humans. Pharmacol Toxicol 61:157-162
2. Peacock L, Lublin H, Gerlach J (1990) The effects of dopamine D1 and D2 receptor agonists and antagonists in monkeys withdrawn from long-term neuroleptic treatment. Eur J Pharmacol 186:49-59
3. Christensen AV (1990) Long-term effects of dopamine D1 and D2 antagonists in vervet monkeys. Behavioral Neurol 3:49-60
4. Gerlach J, Hansen L (1993) Effect of chronic treatment with NNC 756, a new D-1 receptor antagonist, or raclopride, a D-2 receptor antagonist, in drug-naive Cebus monkeys: dystonia, dyskinesia and D1/D2-supersensitivity. J Psychopharm 7:355-364
5. Lublin H, Gerlach J, Peacock L (1993) Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment: extrapyramidal syndromes and dopaminergic supersensitivity. Psychopharmacology 112:389-397
6. Casey DE (1995) The effects of D1 (NC 22-0215) and D2 (haloperidol) antagonists in a double-blind placebo controlled trial in cebus monkeys. Psychopharmacology 121:289-293
7. Collins P, Broekkamp CLE, Jenner P, Marsden CD (1991) Drugs acting at D-1 and D-2 dopamine receptors induce identical purposeless chewing in rats which can be distinguished by cholinergic manipulation. Psychopharmacology 103:503-512
8. Glethøj B, Bolwig TG, Hemmingsen R (1993) Effects of chronic discontinuous and chronic continuous treatment of rats with a dopamine D1 receptor antagonist (NNC-756). Eur J Pharmacol 242:281-2
9. Kakigi T, Gao X-M, Tamminga CA (1995) Drug-induced oral dyskinesias in rats after traditional and new neuroleptics. J Neural Transm (Gen Sect) 101:41-49
10. Nielsen EB, Andersen PH (1992) Dopamine receptor occupancy in vivo: behavioral correlates using NNC-112, NNC-687 and NNC-756, new selective D-1 receptor antagonists. Eur J Pharmacol 219:34-41
11. Waddington JL (1993) Pre- and postsynaptic D1 to D5 receptor mechanisms in relation to antipsychotic activity. In: Barnes T, ed. Antipsychotic Drugs and Their Side Effects. London, San Diego, NY, Boston, Sidney, Tokyo, Toronto: Academic Press, Harcourt, Brace & Company 66-85
12. Peacock L, Hansen L, Mørkeberg F, Gerlach J (1999) Chronic dopamine D1, dopamine D2 and combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys: antiamphetamine effects and extrapyramidal side effects. Neuropsychopharmacology 20:35-43
13. Hess EJ, Albers LJ, Hoang, L, Creese I (1986) Effects of chronic SCH 23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation. J Pharmacol Exp Ther 238:846-854
14. Waddington JL, O'Boyle KM (1987) The D-1 dopamine receptor and the search for its functional role: from neurochemistry to behavior. Rev Neurosci 1:157-184
15. Peacock L, Gerlach J (1997) A reanalysis of the dopamine theory of tardive dyskinesia: the hypothesis of dopamine D1/D2 imbalance. In: Yass R, Nair NPV, Jeste DV, eds. Neuroleptic-Induced Movement Disorders. New York: Cambridge University Press 141-160
16. Cooper JR, Bloom FE, Roth RH, eds (1996) The biochemical basis of neuropharmacology. New York: Oxford University Press 293-351
17. Peacock L, Gerlach J (1999) New and old antipsychotics versus clozapine in a monkey model: adverse effects and antiamphetamine effects. Psychopharmacology 144:189-197
18. Gerlach J (1985) Pathophysiological mechanisms underlying tardive dyskinesia. In: Casey DE, Chase TN, Christensen AV, Gerlach J, eds. Dyskinesia: Reserach and Treatment. Berlin: Springer-Verlag, 1985:118-121
19. Scheel-Kruger J, Arnt J (1985) New aspects on the role of dopamine, acetylcholine and GABA in the development of tradive dyskinesia. In: Casey DE, Chase TN, Christensen TV, Gerlach J, eds. Dyskinesia: Research and Treatment. Berlin: Springer-Verlang, 1985:98-103
20. Gerlach J, Casey DE (1988) Tardive dyskinesia. Acta Psychiatr Scand 77:369-378